Cargando…

Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma

Not many treatment options exist for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in whom first- and second-line therapies were unsuccessful. This is especially true for patients with aggressive lymphomas. The innovative agent pixantrone has shown some promising resul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jezeršek Novaković, Barbara, Boltežar, Lučka, Novaković, Aleksander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936695/ https://www.ncbi.nlm.nih.gov/pubmed/33688197 http://dx.doi.org/10.2147/TCRM.S269324

Ejemplares similares

Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma
por: Novakovic, Aleksander, et al.
Publicado: (2020)

Granulomatosis after autologous stem cell transplantation in nonHodgkin lymphoma – experience of single institution and a review of literature
por: Boltezar, Lucka, et al.
Publicado: (2016)

Fertility in young patients following treatment for Hodgkin’s lymphoma: a single center survey
por: Boltežar, Lučka, et al.
Publicado: (2015)

Correlation of t(14;18) translocation breakpoint site with clinical characteristics in follicular lymphoma
por: Panjan, Matej, et al.
Publicado: (2023)

CD56-positive diffuse large B-cell lymphoma: comprehensive analysis of clinical, pathological, and molecular characteristics with literature review
por: Gasljevic, Gorana, et al.
Publicado: (2023)

Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
por: Novakovic, Barbara Jezersek
Publicado: (2015)

Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma
por: Boltežar, Lučka, et al.
Publicado: (2018)

Long-term outcomes of high dose treatment and autologous stem cell transplantation in follicular and mantle cell lymphomas – a single centre experience
por: Boltezar, Lucka, et al.
Publicado: (2016)

Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
por: Horvat, Matej, et al.
Publicado: (2018)

Trends in specialized palliative care referrals at an oncology center from 2007 to 2019
por: Boltezar, Lucka, et al.
Publicado: (2021)

Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
por: Volpetti, Stefano, et al.
Publicado: (2014)

Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma
por: Rožman, Samo, et al.
Publicado: (2022)

Diagnostic value of immunoglobulin κ light chain gene rearrangement analysis in B-cell lymphomas
por: KOKOVIC, IRA, et al.
Publicado: (2014)

Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma
por: Horvat, Mateja, et al.
Publicado: (2010)

Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010 – a single centre report
por: Jezersek Novakovic, Barbara
Publicado: (2012)

Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome
por: Rozman, Samo, et al.
Publicado: (2017)

The diffuse large B-cell lymphoma – where do we stand now in everyday clinical practice
por: Gregoric, Brigita, et al.
Publicado: (2012)

The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
por: ROŽMAN, SAMO, et al.
Publicado: (2016)

The predictive significance of CD20 expression in B-cell lymphomas
por: Prevodnik, Veronika Kloboves, et al.
Publicado: (2011)

Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision
por: Unk, Mojca, et al.
Publicado: (2023)

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial
por: Pettengell, Ruth, et al.
Publicado: (2016)

An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube
por: Boltežar, Lučka, et al.
Publicado: (2020)

Pixantrone beyond monotherapy: a review
por: Barrenetxea Lekue, Cristina, et al.
Publicado: (2019)

Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity
por: Cerkovnik, Petra, et al.
Publicado: (2010)

Clonality analysis of lymphoid proliferations using the BIOMED-2 clonality assays: a single institution experience
por: Kokovic, Ira, et al.
Publicado: (2014)

Pixantrone Sensitizes Gram-Negative Pathogens to Rifampin
por: She, Pengfei, et al.
Publicado: (2022)

Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial
por: Pettengell, Ruth, et al.
Publicado: (2018)

Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas
por: Poggio, Teresa, et al.
Publicado: (2018)

Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
por: Pytlik, Robert, et al.
Publicado: (2020)

Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma
por: Kelling, Matthew, et al.
Publicado: (2018)

Current approaches to the treatment of non-Hodgkin's lymphoma
por: Gisselbrecht, Christian
Publicado: (2011)

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas
por: Minson, Adrian, et al.
Publicado: (2022)

Correlation of treatment outcome in sanger/RT-qPCR KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumors with next-generation sequencing results: A single-center report
por: Unk, Mojca, et al.
Publicado: (2022)

Bendamustine in the treatment of non-Hodgkin’s lymphomas
por: Hagemeister, Fredrick, et al.
Publicado: (2009)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin’s lymphomas
por: Mohammed, Raihan, et al.
Publicado: (2019)

Peripheral T Cell Non-Hodgkin's Lymphoma following Treatment of Hodgkin's Lymphoma
por: Chang, Sun Hee, et al.
Publicado: (2015)

Outcome of severe infections in afebrile neutropenic cancer patients
por: Strojnik, Ksenija, et al.
Publicado: (2016)

B cell non-Hodgkin's lymphoma: rituximab safety experience
por: Mohrbacher, Ann
Publicado: (2005)

Hodgkin Reed–Sternberg-Like Cells in Non-Hodgkin Lymphoma
por: Parente, Paola, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hr12p6tf4naqv13peo60g8b438